The funding follows the conclusion of the first part of a funding competition — Manufacturing High Value Chemicals through Industrial Biotechnology — run by the Technology Strategy Board (TSB).
The feasibility studies will be conducted by Biocatalysts, Biopharma Technology, Coressence, Demuris, Ensus, Ingenza, Novacta Biosystems, SERE-Tech Innovation, Plaxica and VHsquared.
Each company will receive between £40,000 and £120,000 to carry out the studies. The total cost of the 10 studies, including contributions from the companies, will be in the region of £1.8m.
According to the TSB, the use of industrial biotechnology offers the potential to develop new, efficient and sustainable methods of obtaining a significant proportion of energy, chemical and material needs.
Agricultural feedstocks, novel biocatalysts and bioreactor technologies have the potential to meet a number of challenges, such as replacing existing petrochemical-derived products such as lubricants and plastics or creating active pharmaceutical ingredients through novel bio-transformations.
In April, the TSB will announce the results of the second part of its Manufacturing High Value Chemicals through Industrial Biotechnology funding competition, which will see up to £1.5m invested in a number of collaborative research and development projects.
Record set at EPFL hyperloop test facility
The problem with hyperloops is capacity. High speed and small vehicles limit capacity. Junction design is key. Road vehicles can change lane with...